Meet Pharmidex at KTN 2016
June 14, 2016

Collaboration opportunities in regenerative medicine

Pharmdiex will be attending the Innvoate UK KTN 2016 meeting focused on New Collaboration Opportunities in Regenerative Medicine.

The KTN in collaboration with Innovate UK, Cell and Gene Therapy Catapult, Department of Health and Kings College London are holding an event focussing on new unmet clinical needs, latest developments in regulatory environment and clinical adoption. Following recent developments and the UK’s Regenerative Medicine Expert Group report recommendations, this event will bring together the UK regenerative medicine communities involving industrialists, academics and clinicians from a number of clinical specialities.


The UK is leading the field in the development of cell and gene therapies. The regulatory system now has a number of mechanisms to accelerate the progress of promising therapies including EAMS and the proposed new PRIME scheme. However, practical challenges still exist to the clinical adoption of these new therapies and getting them to patients, including generating sufficient clinical data, achieving reimbursement and embedding therapies in existing or new clinical pathways).


Leading clinicians and experts from a number of organisations will be presenting at this event. Directors and managers from major funding organisations, e.g. Innovate UK, Research Councils, relevant charities will also be invited to support this event.


The main aims of this event are as follows;


  • To discuss challenges affecting clinical adoption of cell and gene-based therapies.
  • Facilitate new clinician/industry collaborations in a number of areas of clinical specialities.
  • Identify barriers to innovation and commercialisation.
  • Review current funding opportunities and identify funding gaps.
  • Provide networking opportunities to identify collaborating partners.
  • Review supporting mechanisms available to accelerate innovation and commercialisation through KTN and partners Innovate UK, Cell and Gene Therapy Catapult organisations.
  • Review current pre-clinical and clinical trials and identify best practice to accelerate regulatory approvals


For more information please see the following link: https://www.eventbrite.co.uk/e/new-collaboration-opportunities-in-regenerative-medicine-tickets-24454460951

January 29, 2026
Pharmidex is delighted to share that Ash Alavijeh , Head of Operations, will be attending the UK BioIndustry Association (BIA) Annual Gala Dinner at the Roundhouse, London. Ash is looking forward to connecting with pharma and biotech colleagues to explore new collaborations, partnerships, and opportunities, all with the shared goal of advancing drug discovery and development. If you’re attending, feel free to connect with Ash this evening.
January 26, 2026
Pharmidex provides comprehensive biomarker and cytokine profiling services to support drug discovery and development across respiratory, autoimmune, metabolic and toxicology programmes. Using state-of-the-art bioanalytical platforms, we deliver robust, translational biomarker data to help understand mechanism of action, immune modulation and therapeutic efficacy. Let’s talk about how our biomarker expertise can strengthen your research. 🌐 https://www.pharmidex.com/BIOMARKERS_ANALYSIS
January 21, 2026
We’re delighted to share that Vasudha Tandon, PhD Principal Scientist at Pharmidex , will be attending the BBMS Gala Dinner 2026 on Thursday 22 January 2026 at the Old Hall, Queens’ College, Cambridge. This special evening, part of Building Bridges in Medical Sciences, brings together leaders from academia, industry, and healthcare to strengthen collaboration across the life sciences. Vasudha is looking forward to meeting fellow attendees and exploring new opportunities to build meaningful scientific partnerships.
More Posts